Tenax Therapeutics, Inc. (TENX) stock
TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.62+0.01 (+0.62%)
Close on Nov 13, 2026Market cap $60.63MP/E –Yield –
Tenax Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Tenax Therapeutics's EPS for the twelve months ending Sep 30, 2026 was -$1.39. For fiscal 2025 it was -$1.34. The highest annual figure on record is -$0.95 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.34 | – |
| FY2024 | Dec 31, 2024 | -$1.15 | – |
| FY2023 | Dec 31, 2023 | -$31.04 | – |
| FY2021 | Dec 31, 2021 | -$1.58 | – |
| FY2020 | Dec 31, 2020 | -$0.95 | – |
| FY2019 | Dec 31, 2019 | -$1.35 | – |
| FY2018 | Dec 31, 2018 | -$9.04 | – |
| FY2017 | Dec 31, 2017 | -$6.27 | – |
| FY2015 | Apr 30, 2015 | -$10.00 | – |
| FY2014 | Apr 30, 2014 | -$54.20 | – |
| FY2013 | Apr 30, 2013 | -$133.60 | – |
| FY2012 | Apr 30, 2012 | -$281.40 | – |
| FY2011 | Apr 30, 2011 | -$180.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | -$0.31 | – |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$0.35 | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$0.35 | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$0.38 | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$0.40 | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$0.27 | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$0.28 | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$0.19 | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$1.83 | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$3.12 | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$0.15 | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$0.10 | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$1.64 | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$0.18 | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$0.23 | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$0.38 | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$0.33 | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$0.28 | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$0.33 | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$1.05 | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$1.28 | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$0.84 | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -$0.87 | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$2.12 | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$2.33 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?